Bill Text: NJ ACR99 | 2016-2017 | Regular Session | Introduced
Bill Title: Urges Congress to pass legislation funding personalized medicine.
Sponsorship: Partisan Bill (Democrat 3)
Status: (Introduced - Dead) 2016-01-27 - Introduced, Referred to Assembly Health and Senior Services Committee [ACR99 Detail]
Download: New_Jersey-2016-ACR99-Introduced.html
ASSEMBLY CONCURRENT RESOLUTION No. 99
STATE OF NEW JERSEY
217th LEGISLATURE
PRE-FILED FOR INTRODUCTION IN THE 2016 SESSION
Sponsored by:
Assemblyman LOUIS D. GREENWALD
District 6 (Burlington and Camden)
Assemblyman GARY S. SCHAER
District 36 (Bergen and Passaic)
Co-Sponsored by:
Assemblywoman Pinkin
SYNOPSIS
Urges Congress to pass legislation funding personalized medicine.
CURRENT VERSION OF TEXT
Introduced Pending Technical Review by Legislative Counsel.
A Concurrent Resolution urging Congress to pass legislation funding personalized medicine.
Whereas, The completion of the Human Genome Project--the research effort to determine the DNA sequence of the human genome--in 2003 paved the way for a more sophisticated understanding of disease causation, which has contributed to the advent of "personalized medicine": and
Whereas, Personalized medicine, also referred to as "precision medicine," is a medical model that proposes the customization of healthcare with medical decisions, practices, and products being tailored to a patient's unique genetic makeup, taking into account individual variability in genes, environment, and lifestyle for each person; and
Whereas, Personalized medicine is dependent upon laboratories rapidly developing unique tests that include genetic sequencing and can be brought to patients without delay. These tests, called Laboratory Developed Tests (LDTs), have led to recently developed treatments for cancer, cystic fibrosis, and other areas with unmet medical need; and
Whereas, In some patients with cystic fibrosis--a disease which clogs the lungs with thick, sticky mucus--this approach has reversed a disease once thought unstoppable, with the U.S. Food and Drug Administration (FDA) approving a drug for patients with a genetic mutation responsible for some cases of the disease; and
Whereas, On January 30, 2015, President Obama outlined the "Precision Medicine Initiative," a $215 million research effort to collect genetic information from at least one million Americans--one of the largest research populations ever--with the hope of developing personalized treatments to prevent and treat disease; and
Whereas, The initiative includes $130 million for the National Institutes of Health (NIH) to create a nationwide pool of volunteers so that researchers can study their genes, lifestyles and environments; and
Whereas, The National Cancer Institute (NCI) would receive $70 million to identify genes that cause different types of cancer, and then use that information to develop new treatments to target those abnormal genes; and
Whereas, $10 million would be allotted for the FDA to develop new methods for evaluating next-generation genetic tests; and
Whereas, Recognizing the key role that new technology, data capture, and transparency will play in the progression of medicine, the Office of the National Coordinator for Health Information Technology (ONC) would receive $5 million to ensure that data is exchanged securely and privately; and
Whereas, By engaging the NIH, the FDA, and the ONC, this initiative represents a significant interagency collaboration that can move science forward rapidly and effectively to better serve the health care needs of patients; and
Whereas, This initiative is a major step toward building a stronger public-private partnership to leverage health data and technology to accelerate the discovery and development of tailored treatments for patients; and
Whereas, Nurturing pathways for innovation and new discoveries, effectively driven by clinical laboratories, is essential for patients to receive the latest precision medicine that holds the best promise for effective treatment; and
Whereas, Precision medicine requires additional and ongoing research to ensure that health care decisions are based on and supported by the best available evidence; and
Whereas, Funding of the initiative, which is part of the President's budget request for the 2016 fiscal year, is subject to congressional approval; now, therefore,
Be It Resolved by the General Assembly of the State of New Jersey (the Senate concurring):
1. The Congress of the United States is urged to pass legislation funding personalized medicine.
2. Copies of this resolution, as filed with the Secretary of State, shall be transmitted by the Clerk of the General Assembly or the Secretary of the Senate to the President and Vice President of the United States, the Majority and Minority Leaders of the United States Senate, the Speaker and Majority and Minority Leaders of the United States House of Representatives, and each member of the United States Congress elected from this State.
STATEMENT
This concurrent resolution urges the United States Congress to enact legislation to ensure ongoing funding for personalized medicine, which is a customized form of health care tailored to each patient's unique characteristics, including that patient's genes, environment, and lifestyle. Personalized medicine, which is also known as "precision medicine," has led to new developments in treating conditions as cancer and cystic fibrosis. The Precision Medicine Initiative was first proposed in January 2015 as a $215 million research effort involving a diverse partnership of public and private entities working to bring together health data and technology, with the goal of advancing the development of new tailored treatments and procedures. Ongoing funding for the Precision Medicine Initiative is necessary to continue and expand these efforts.
